Leo Pharma strongly criticizes Danish Medicines Council

A letter from Leo Pharma to the agency reveals that the pharmaceutical company is not satisfied with the Danish Medicines Council's assessment of eczema treatment Adtralza.

Photo: Leo Pharma / PR

Once again, the Danish Medicines Council has come under fire. According to Leo Pharma, the council has used the wrong methods to evaluate its eczema treatment Adtralza, affecting several assessment criteria.

This news was reported by Dagens Pharma, which has seen a letter Leo Pharma Nordic sent to the Danish Medicines Council.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs